Clinical Trials with External Control: Beyond Propensity Score Matching

Hongwei Wang (), Yixin Fang, Weili He, Ruizhe Chen and Su Chen
Additional contact information
Hongwei Wang: Data and Statistical Sciences, AbbVie
Yixin Fang: Data and Statistical Sciences, AbbVie
Weili He: Data and Statistical Sciences, AbbVie
Ruizhe Chen: University of Illinois Chicago
Su Chen: Data and Statistical Sciences, AbbVie

Statistics in Biosciences, 2022, vol. 14, issue 2, No 7, 304-317

Abstract: Abstract Real-world data (RWD) is playing an increasingly important role in drug development from early discovery throughout the life-cycle management. This includes leveraging RWD in randomized clinical trial (RCT) design and study conduct. In many scenarios, a concurrent control arm may not be viable for ethical or practical considerations, and inclusion of an external control arm can greatly facilitate the decision-making and interpretation of findings. We summarize the strengths and limitations of typical external data sources including historical RCT, aggregated data at study level from literature, patient registry, health insurance claims, electronic health records in terms of fit-for-purpose data selection. To address the inherent confounding due to lack of randomization, propensity score matching method has the advantages of separating the design from analysis and providing the ability to explicitly examine the degree of overlap in confounders. Within the framework of causal inference, however, many alternatives have been proposed with desirable theoretical properties. In this article, we review key steps from study design conceptualization to data source selection, and focus on several methods for evaluation of performance in the context of creating external control for clinical trials. We conducted a focused simulation studies to assess bias reduction and statistical properties when underlying assumptions are violated or models are mis-specified. The results support that analysis using matched group improve bias reduction when sample size is not a limiting factor, and targeted maximum likelihood estimation coupled with super learner is robust when estimating both average treatment effects and average treatment effects among treated.

Keywords: External control; Clinical trials; Causal inference; Propensity score; Doubly robust; Targeted MLE (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s12561-022-09341-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:stabio:v:14:y:2022:i:2:d:10.1007_s12561-022-09341-x

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/12561

DOI: 10.1007/s12561-022-09341-x

Access Statistics for this article

Statistics in Biosciences is currently edited by Hongyu Zhao and Xihong Lin

More articles in Statistics in Biosciences from Springer, International Chinese Statistical Association
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().